@misc{noauthor_neuropsychiatric_nodate,
	title = {Neuropsychiatric {Drug} {Developers} {Show} a {Renewed} {Sense} of {Purpose}: {Therapeutics} for depression, schizophrenia, and other neuropsychiatric disorders are targeting inflammation, stimulating neurogenesis, and taking cues from biomarkers: {Genetic} {Engineering} \& {Biotechnology} {News}: {Vol} 41, {No} 11},
	url = {https://www.liebertpub.com/doi/10.1089/gen.41.11.13},
	urldate = {2021-12-21},
}

{"_id":"mqhAuw28sQW9ZmppG","bibbaseid":"anonymous-neuropsychiatricdrugdevelopersshowarenewedsenseofpurposetherapeuticsfordepressionschizophreniaandotherneuropsychiatricdisordersaretargetinginflammationstimulatingneurogenesisandtakingcuesfrombiomarkersgeneticengineeringbiotechnologynewsvol41no11","bibdata":{"bibtype":"misc","type":"misc","title":"Neuropsychiatric Drug Developers Show a Renewed Sense of Purpose: Therapeutics for depression, schizophrenia, and other neuropsychiatric disorders are targeting inflammation, stimulating neurogenesis, and taking cues from biomarkers: Genetic Engineering & Biotechnology News: Vol 41, No 11","url":"https://www.liebertpub.com/doi/10.1089/gen.41.11.13","urldate":"2021-12-21","bibtex":"@misc{noauthor_neuropsychiatric_nodate,\n\ttitle = {Neuropsychiatric {Drug} {Developers} {Show} a {Renewed} {Sense} of {Purpose}: {Therapeutics} for depression, schizophrenia, and other neuropsychiatric disorders are targeting inflammation, stimulating neurogenesis, and taking cues from biomarkers: {Genetic} {Engineering} \\& {Biotechnology} {News}: {Vol} 41, {No} 11},\n\turl = {https://www.liebertpub.com/doi/10.1089/gen.41.11.13},\n\turldate = {2021-12-21},\n}\n\n\n\n\n\n\n\n","key":"noauthor_neuropsychiatric_nodate","id":"noauthor_neuropsychiatric_nodate","bibbaseid":"anonymous-neuropsychiatricdrugdevelopersshowarenewedsenseofpurposetherapeuticsfordepressionschizophreniaandotherneuropsychiatricdisordersaretargetinginflammationstimulatingneurogenesisandtakingcuesfrombiomarkersgeneticengineeringbiotechnologynewsvol41no11","role":"","urls":{"Paper":"https://www.liebertpub.com/doi/10.1089/gen.41.11.13"},"metadata":{"authorlinks":{}},"downloads":0},"bibtype":"misc","biburl":"https://bibbase.org/zotero/saracatanese","dataSources":["eTsH756eicg6vxuG3"],"keywords":[],"search_terms":["neuropsychiatric","drug","developers","show","renewed","sense","purpose","therapeutics","depression","schizophrenia","neuropsychiatric","disorders","targeting","inflammation","stimulating","neurogenesis","taking","cues","biomarkers","genetic","engineering","biotechnology","news","vol"],"title":"Neuropsychiatric Drug Developers Show a Renewed Sense of Purpose: Therapeutics for depression, schizophrenia, and other neuropsychiatric disorders are targeting inflammation, stimulating neurogenesis, and taking cues from biomarkers: Genetic Engineering & Biotechnology News: Vol 41, No 11","year":null}